2025
Endovascular Embolization versus Observation of Congenital Renal Arteriovenous Malformations: A Retrospective Study
Hufnagle J, Fish A, Schlachter T. Endovascular Embolization versus Observation of Congenital Renal Arteriovenous Malformations: A Retrospective Study. Journal Of Vascular And Interventional Radiology 2025, 36: 988-993.e1. PMID: 39938714, DOI: 10.1016/j.jvir.2025.02.001.Peer-Reviewed Original ResearchCongenital renal arteriovenous malformationRenal arteriovenous malformationType I AVMArteriovenous malformationsEndovascular embolizationAdverse eventsImaging review of patientsReview of patientsArteriovenous malformation ruptureFollow-up dataYakes classificationTransarterial embolizationEmbolization groupPresenting symptomsPatient demographicsRetrospective studyProcedural imagingImaging reviewEmbolizationPatientsObservation groupMalformationsComplicationsVessel sizeNephrectomy
2021
Leukocytoclastic Vasculitis and Microvascular Occlusion Key Concepts for the Working Pathologist
Ko CJ, Gehlhausen JR, McNiff JM. Leukocytoclastic Vasculitis and Microvascular Occlusion Key Concepts for the Working Pathologist. Surgical Pathology Clinics 2021, 14: 309-325. PMID: 34023108, DOI: 10.1016/j.path.2021.01.006.Peer-Reviewed Original ResearchConceptsLeukocytoclastic vasculitisMicrovascular occlusionSmall vessel leukocytoclastic vasculitisMedium-sized vesselsSame differential diagnosisBiopsy findingsDermal involvementSystemic diseaseCertain infectionsDifferential diagnosisVasculitisDepth of involvementClinical diagnosisOcclusionDiagnosisVessel sizeInvolvementVesselsSize of vesselsCalciphylaxis
2006
Effect of Everolimus-Eluting Stents in Different Vessel Sizes (from the Pooled FUTURE I and II Trials)
Tsuchiya Y, Lansky AJ, Costa RA, Mehran R, Pietras C, Shimada Y, Sonoda S, Cristea E, Negoita M, Dangas GD, Moses JW, Leon MB, Fitzgerald PJ, Müller R, Störger H, Hauptmann KE, Grube E. Effect of Everolimus-Eluting Stents in Different Vessel Sizes (from the Pooled FUTURE I and II Trials). The American Journal Of Cardiology 2006, 98: 464-469. PMID: 16893698, DOI: 10.1016/j.amjcard.2006.02.054.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlood Vessel Prosthesis ImplantationCoated Materials, BiocompatibleCoronary AngiographyCoronary RestenosisCoronary VesselsEverolimusFemaleFollow-Up StudiesHumansImmunosuppressive AgentsMaleMiddle AgedProspective StudiesProsthesis DesignSirolimusStentsTreatment OutcomeUltrasonography, InterventionalConceptsBare metal stentsDe novo coronary lesionsNovo coronary lesionsCoronary lesionsNeointimal proliferationStent late lumen lossMid-term outcomesLate lumen lossEverolimus-Eluting StentsQuantitative coronary angiographyMinimum lumen areaVessel sizeII trialCoronary angiographyI trialIncomplete appositionLumen lossStent thrombosisAneurysm formationStent restenosisIntravascular ultrasoundMetal stentsReference diameterLumen areaPatients
2005
Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668
Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ. Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668. Clinical Cancer Research 2005, 11: 678-689. PMID: 15701856, DOI: 10.1158/1078-0432.678.11.2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnimalsApoptosisDose-Response Relationship, DrugEndothelium, VascularFemaleHumansIndolesMaleMiceMice, NudeMiddle AgedNeovascularization, PathologicOxindolesPancreatic NeoplasmsPhosphorylationPropionatesPyrrolesReceptor, Platelet-Derived Growth Factor betaTransplantation, HeterologousVascular Endothelial Growth Factor Receptor-2ConceptsPlatelet-derived growth factor receptorTumor microvessel densityGrowth factor receptorMicrovessel densityCell apoptosisVascular endothelial growth factor receptorAdvanced solid malignanciesFactor receptorEndothelial growth factor receptorPrimary patient tumorsG core biopsyDose-dependent effectPhosphorylated VEGFR-2Primary human tumorsEndothelial cell deathCell deathEndothelial cell apoptosisTumor cell apoptosisTumor cell deathPost therapyCore biopsyPharmacodynamic analysisSolid malignanciesVessel sizeClinical trials
2003
Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of in-stent restenosis
Shirai K, Lansky AJ, Mintz GS, Costantini CO, Fahy M, Mehran R, Dangas G, Moses JW, Stone GW, Waksman R, Leon MB. Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of in-stent restenosis. The American Journal Of Cardiology 2003, 92: 1409-1413. PMID: 14675575, DOI: 10.1016/j.amjcard.2003.08.047.Peer-Reviewed Original ResearchConceptsMinimum lumen diameterVascular brachytherapyLesion lengthSegment restenosisAngiographic outcomesStent restenosisFinal minimum lumen diameterRandomized clinical trialsIndependent angiographic predictorsAngiographic restenosisPlacebo groupAngiographic predictorsAngiographic resultsMultivariable analysisNative coronariesVessel sizeClinical trialsLesion complexityVBT groupRestenosisLumen diameterSimilar reductionPlaceboGreater reductionLesions
2002
Does vessel size have an impact on recurence rates following gamma vascular brachytherapy: acute and nine-month results from SCRIPPS III registry
Adamian M, Mehran R, Dangas G, New G, Abizaid A, Lansky A, Weisz G, Grise M, Collins M, Kreps E, Stone G, Moussa I, Moses J, Leon M, Teirstein P. Does vessel size have an impact on recurence rates following gamma vascular brachytherapy: acute and nine-month results from SCRIPPS III registry. Journal Of The American College Of Cardiology 2002, 39: 64. DOI: 10.1016/s0735-1097(02)80277-7.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply